Matt Miksic
Stock Analyst at Barclays
(3.88)
# 723
Out of 4,412 analysts
136
Total ratings
60.67%
Success rate
4.57%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Overweight | $70 → $78 | $73.17 | +6.60% | 7 | Apr 26, 2024 | |
| ABT Abbott Laboratories | Maintains: Overweight | $141 → $140 | $107.53 | +30.20% | 17 | Apr 22, 2024 | |
| INMD InMode | Maintains: Overweight | $34 → $33 | $17.14 | +92.53% | 8 | Apr 12, 2024 | |
| ZIMV ZimVie | Maintains: Underweight | $13 → $16 | $15.82 | +1.14% | 7 | Mar 5, 2024 | |
| LIVN LivaNova | Maintains: Equal-Weight | $57 → $61 | $55.53 | +9.85% | 5 | Feb 27, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $214 → $213 | $166.19 | +28.17% | 4 | Feb 26, 2024 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $18 | $14.79 | +21.70% | 4 | Feb 26, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $120 → $130 | $119.35 | +8.92% | 4 | Feb 12, 2024 | |
| BAX Baxter International | Maintains: Overweight | $52 → $54 | $40.13 | +34.56% | 9 | Feb 12, 2024 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $385 → $430 | $375.33 | +14.57% | 4 | Jan 25, 2024 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $158 → $162 | $146.14 | +10.85% | 9 | Oct 12, 2023 | |
| GMED Globus Medical | Maintains: Overweight | $77 → $86 | $50.55 | +70.13% | 6 | Oct 12, 2023 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $71 → $62 | $35.24 | +75.94% | 2 | Aug 7, 2023 | |
| SYK Stryker | Maintains: Overweight | $321 → $335 | $335.61 | -0.18% | 7 | Aug 7, 2023 | |
| DXCM DexCom | Maintains: Equal-Weight | $115 → $138 | $124.34 | +10.99% | 4 | Jul 31, 2023 | |
| EW Edwards Lifesciences | Maintains: Overweight | $94 → $102 | $86.43 | +18.01% | 8 | Apr 28, 2023 | |
| MDT Medtronic | Upgrades: Overweight | $89 → $104 | $79.74 | +30.42% | 8 | Apr 24, 2023 | |
| ALC Alcon | Assumes: Outperform | $96 | $78.77 | +21.87% | 6 | May 13, 2022 | |
| HSIC Henry Schein | Assumes: Outperform | $100 | $73.13 | +36.74% | 3 | May 13, 2022 | |
| ALGN Align Technology | Maintains: Outperform | $722 → $418 | $309.02 | +35.27% | 3 | May 4, 2022 | |
| SHC Sotera Health Company | Maintains: Outperform | $31 → $28 | $11.40 | +145.61% | 2 | Mar 2, 2022 | |
| XRAY DENTSPLY SIRONA | Maintains: Outperform | $68 → $67 | $30.57 | +119.17% | 1 | Mar 1, 2022 | |
| RBOT Vicarious Surgical | Initiates: Outperform | $16 | $0.27 | +5,825.93% | 1 | Jan 7, 2022 | |
| IART Integra LifeSciences Holdings | Maintains: Outperform | n/a | $28.34 | - | 5 | Nov 3, 2021 | |
| ORGO Organogenesis Holdings | Maintains: Outperform | n/a | $2.35 | - | 1 | Aug 10, 2021 | |
| MDXG MiMedx Group | Initiates: Sell | n/a | $6.27 | - | 1 | Dec 12, 2016 |
Boston Scientific
Apr 26, 2024
Maintains: Overweight
Price Target: $70 → $78
Current: $73.17
Upside: +6.60%
Abbott Laboratories
Apr 22, 2024
Maintains: Overweight
Price Target: $141 → $140
Current: $107.53
Upside: +30.20%
InMode
Apr 12, 2024
Maintains: Overweight
Price Target: $34 → $33
Current: $17.14
Upside: +92.53%
ZimVie
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $15.82
Upside: +1.14%
LivaNova
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $57 → $61
Current: $55.53
Upside: +9.85%
Insulet
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $214 → $213
Current: $166.19
Upside: +28.17%
Bausch + Lomb
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $14.79
Upside: +21.70%
Zimmer Biomet Holdings
Feb 12, 2024
Maintains: Underweight
Price Target: $120 → $130
Current: $119.35
Upside: +8.92%
Baxter International
Feb 12, 2024
Maintains: Overweight
Price Target: $52 → $54
Current: $40.13
Upside: +34.56%
Intuitive Surgical
Jan 25, 2024
Maintains: Overweight
Price Target: $385 → $430
Current: $375.33
Upside: +14.57%
Johnson & Johnson
Oct 12, 2023
Maintains: Equal-Weight
Price Target: $158 → $162
Current: $146.14
Upside: +10.85%
Globus Medical
Oct 12, 2023
Maintains: Overweight
Price Target: $77 → $86
Current: $50.55
Upside: +70.13%
Tandem Diabetes Care
Aug 7, 2023
Maintains: Overweight
Price Target: $71 → $62
Current: $35.24
Upside: +75.94%
Stryker
Aug 7, 2023
Maintains: Overweight
Price Target: $321 → $335
Current: $335.61
Upside: -0.18%
DexCom
Jul 31, 2023
Maintains: Equal-Weight
Price Target: $115 → $138
Current: $124.34
Upside: +10.99%
Edwards Lifesciences
Apr 28, 2023
Maintains: Overweight
Price Target: $94 → $102
Current: $86.43
Upside: +18.01%
Medtronic
Apr 24, 2023
Upgrades: Overweight
Price Target: $89 → $104
Current: $79.74
Upside: +30.42%
Alcon
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $78.77
Upside: +21.87%
Henry Schein
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $73.13
Upside: +36.74%
Align Technology
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $309.02
Upside: +35.27%
Sotera Health Company
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.40
Upside: +145.61%
DENTSPLY SIRONA
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $30.57
Upside: +119.17%
Vicarious Surgical
Jan 7, 2022
Initiates: Outperform
Price Target: $16
Current: $0.27
Upside: +5,825.93%
Integra LifeSciences Holdings
Nov 3, 2021
Maintains: Outperform
Price Target: n/a
Current: $28.34
Upside: -
Organogenesis Holdings
Aug 10, 2021
Maintains: Outperform
Price Target: n/a
Current: $2.35
Upside: -
MiMedx Group
Dec 12, 2016
Initiates: Sell
Price Target: n/a
Current: $6.27
Upside: -